Minster Pharmaceuticals plc, through its subsidiary, Minster Research Limited, develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions in the United Kingdom. Its products pipeline comprises Tonabersat, which is in Phase IIb clinical trial for the prevention and treatment of migraine; and Sabcomeline, a Phase IIa clinical trial product for the management of cognitive decline and negative symptoms in schizophrenia. The company is based in Saffron Walden, the United Kingdom.

Ben Venue Laboratories prides itself on having products that are clean, clear, and cold. A subsidiary of German drug firm Boehringer Ingelheim, the company provides contract manufacturing services, including product and process development and regulatory compliance services. The company specializes in manufacturing liquid and lyophilized (freeze-dried) pharmaceuticals. Ben Venue's Bedford Laboratories division provides contract manufacturing of generic injectable pharmaceuticals. Customers include multinational drugmakers, small biotech development firms, and government agencies.

Noramco, a subsidiary of healthcare giant Johnson & Johnson, makes active pharmaceutical ingredients used in the medications and medical devices made by Johnson and Johnson subsidiaries (including Ortho-McNeil Pharmaceutical, Janssen, and Ethicon), as well as third parties. The company was founded in 1979 to support the manufacture of Ortho-McNeil's Tylenol with codeine product line. It is one of a very few US companies allowed by the DEA to import such controlled substances as opium for use in painkillers like oxycodone and morphine. Noramco operates two manufacturing facilities in Athens, Georgia, and Wilmington, Delaware.

Samaritan Pharmaceuticals, Inc. was founded in 1994 and is based in Las Vegas, Nevada. Samaritan Pharmaceuticals, Inc. (Samaritan) is an entrepreneurial biopharmaceutical company, focused on commercializing therapeutic products to relieve the suffering of patients with Alzheimer's disease, cancer, cardiovascular disease, human immunodeficiency virus (HIV), and Hepatitis C. Samaritan also focuses on commercializing its acquired marketing and sales rights to sell marketed revenue-generating products, in Greece, and/or various Eastern European countries. The Company has partnered its oral entry inhibitor HIV drug SP-01A, a drug that has demonstrated efficacy, in Phase II clinical trials, with Pharmaplaz, Ireland to advance to Phase III clinical trials. In addition, it focuses on commercializing three market drug candidates with late-stage preclinical development programs.

BioSyntech is a development-stage company specializing in the creation and development of biotherapeutic thermogels to be used for human tissue repair and therapeutic delivery. The BST-Gels are liquid at room temperature but solidify at human body temperature, and they are classified as medical devices by the FDA and other regulators. Various products in development include BST-CarGel (cartilage repair), BST-InPod (heel cushioning), and BST-DermOn (chronic wound healing). For now, the company makes its money primarily from the sale of Ultrasan, a pure form of chitosan (derived from chitin and is also used in the thermogels), and providing analytical services to support Ultrasan.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

K-V Pharmaceutical Company (KV) is a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets branded and generic/non-branded prescription pharmaceutical products. The Company has a range of dosage form capabilities, including tablets, capsules, creams, liquids and ointments. KV conducts its branded pharmaceutical operations through Ther-Rx Corporation (Ther-Rx) and its generic/non-branded pharmaceutical operations through ETHEX Corporation (ETHEX). Through Particle Dynamics, Inc. (PDI), the Company also develops, manufactures and markets value-added raw material products for the pharmaceutical, nutritional, personal care, food and other markets. The Company has developed a variety of drug delivery and formulation technologies, which are primarily focused in four principal areas: SITE RELEASE; tastemasking; oral controlled release, and oral quick dissolving tablets.

GlaxoSmithKline Research & Development is the actual pipeline filled with products in various stages of completion for pharmaceutical giant GlaxoSmithKline. With multiple locations in the US, across Europe, and Japan, the company has treatments in the works for ailments such as infectious diseases, neuroscientific requirements, cardiovascular ailments, oncology, and respiratory needs. It has approximately 150 pharmaceutical products in clinical trial stages. The organization's facilities are grouped into Molecular Discovery Research (preclinical), Centres of Excellence for Drug Discovery (early stage clinical), and Medicine Development Centres (late-stage clinical).

La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California. La Jolla Pharmaceutical aimed to eliminate diseases. The development-stage firm was working with Toleragens, proprietary therapies that block the abnormal antibody production associated with certain autoimmune disorders without suppressing the entire immune system. Its lead drug candidate was Riquent, a treatment for renal disease associated with lupus. The drug would have been one of the few new drugs for lupus, and was being considered as a treatment for other autoimmune disorders. However, the company ceased most of its operations after trials of Riquent failed in 2009. Adamis Pharmaceuticals has announced it intends to acquire La Jolla Pharmaceuticals.

Streck, Inc. company was founded in 1971 and is based in Omaha, Nebraska. Streck, Inc. develops and manufactures hematology, chemistry, and immunology products for the clinical laboratory in the United States, Japan, and internationally. It offers controls for automated hematology instruments, and hematology controls, reagents, and support products; controls for immunophenotyping by flow cytometry; A1c-Cellular, a blood cellular control product for instruments measuring HbA1c; and UA-Cellular for IQ that provides a thorough evaluation of the iQ instrument's ability to identify and quantify white blood cells, red blood cells, non-squamous epithelial cells, and crystals. The company also provides hematology reagents, which include diluents, lysing agents, enzymatic cleansers, and detergents; quality control devices, including the red spirit thermometers with scales in 1/2-degree increments to monitor refrigerators, freezers, and incubators/room temperatures; and automated erythrocyte sedimentation rate (ESR) analyzers. In addition, it offers technical services.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.